KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Inventory: 2018-2024

Historic Inventory for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $8.4 million.

  • Adaptive Biotechnologies' Inventory fell 16.91% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 16.91%. This contributed to the annual value of $8.4 million for FY2024, which is 41.58% down from last year.
  • As of FY2024, Adaptive Biotechnologies' Inventory stood at $8.4 million, which was down 41.58% from $14.4 million recorded in FY2023.
  • Over the past 5 years, Adaptive Biotechnologies' Inventory peaked at $19.3 million during FY2021, and registered a low of $8.4 million during FY2024.
  • Moreover, its 3-year median value for Inventory was $14.4 million (2023), whereas its average is $12.4 million.
  • Its Inventory has fluctuated over the past 5 years, first surged by 55.07% in 2020, then plummeted by 41.58% in 2024.
  • Adaptive Biotechnologies' Inventory (Yearly) stood at $14.1 million in 2020, then soared by 36.98% to $19.3 million in 2021, then decreased by 24.97% to $14.5 million in 2022, then fell by 0.03% to $14.4 million in 2023, then plummeted by 41.58% to $8.4 million in 2024.